Cohance Lifesciences share price
NSE: COHANCEBSE: 543064Pharmaceuticals & BiotechnologySmall Cap
Cohance Lifesciences Limited · Formerly Suven Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2020
Last close ₹444.30down ₹37.05 (7.70%)BSE ₹444.45
Share price at the NSE close on 30 Oct 2026. Previous close ₹481.35.
30 Oct: open ₹478.00, high ₹481.30, low ₹442.15
52-week range of traded prices to 30 Oct 2026
₹266.70Low, 9 Mar 2026₹794.75High, 30 Oct 2025
- Next results date: the board meets on 6 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹16,999 Cr428th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 160.02
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 133.22
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 3.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹21 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 4.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 3.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.04
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 14,97,28643.3% delivered
About Cohance Lifesciences
Cohance Lifesciences is a Hyderabad-based contract development and manufacturing organisation (CDMO), which develops and makes medicines and their ingredients for innovators (companies that discover new drugs), biotechnology companies and generic drug makers.12 It specialises in small molecules, antibody-drug conjugates (ADCs, cancer drugs that link an antibody to a payload) and oligonucleotides (short genetic strands used as medicines), with plants in India and the US serving North America, Europe and Japan.1
The business runs as Pharma CDMO, API+ (drug active ingredients through to pellets and finished formulations) and Speciality Chemicals, which makes crop-protection molecules with agrochemical innovators and performance chemicals for display electronics and coatings.324 Its subsidiaries include Sapala Organics in India, which makes oligonucleotide building blocks, and NJ Bio Inc in New Jersey, which offers payload-linker chemistry, bioconjugation (attaching a drug to an antibody), analytics and translational research.54
It was incorporated in 2018.6 The earlier Cohance Lifesciences Limited, which had bought a 67.5% stake in Sapala Organics in July 2024 for ₹258 crore, was amalgamated into the company with effect from 1 May 2025.78 Umang Vohra is executive chairman and group chief executive.9
Cohance Lifesciences key points
Results
- In the year to Mar 2026, consolidated revenue from operations fell 13.0% to ₹2,268.55 crore, or 3.5% excluding customer destocking in Pharma CDMO; profit attributable to shareholders was ₹179.23 crore, and total profit including minority owners ₹150.12 crore.10
- Consolidated adjusted EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹477 crore in the year to Mar 2026, a 21% margin; gross margin rose 209 basis points to 70.8%.1112
- In the quarter to Jun 2026, consolidated revenue fell 23.1% to ₹4,223 million; adjusted EBITDA was ₹92 million, a 2.2% margin, and the adjusted loss after tax was ₹430 million.13
- Net cash (cash and liquid investments less borrowings) was ₹2,512 million on 30 Jun 2026.14
Business segments
- Share of revenue by segment151617In the quarter to Jun 2026, API+ revenue fell 10.4% and Speciality Chemicals revenue 34.7% from a year earlier.
Item quarter to Jun 2026 year to Mar 2026 API+ 62% 48% Pharma CDMO 30% 39% Speciality Chemicals 8% 13% - Subsidiaries. Sapala's revenue grew 2.5 times to ₹274 million in the quarter to Jun 2026; NJ Bio had revenue of ₹350 million and an adjusted EBITDA loss of ₹328 million.18
- API+. API+ centres on ingredients for central nervous system (CNS) drugs.19
Where revenue comes from
- Exports made up 84% of standalone turnover in the year to Mar 2026, and the company served customers in 59 countries.20
Plants and capacity
- Cohance has 13 manufacturing plants, 8 audited by the US FDA: 7 for API+, 5 for Pharma CDMO and 1 for Speciality Chemicals, with over 3,000 kilolitres (KL) of standalone capacity.112122
- Installed capacity is 1,242 KL a year for APIs, and 5.3 billion tablets and capsules, 650 metric tonnes of pellets and 68 million liquid bottles and tubes for formulations.23
- Capital spending was ₹215 crore in the year to Mar 2026 and ₹598 million in the quarter to Jun 2026.2425
- The company stated in its annual report for the year to Mar 2026 that a US$10 million bioconjugation suite was under way at NJ Bio and a ₹23 crore Nacharam plant for oligonucleotide building blocks, of up to 700 kg a year, was under validation.26
Customers and partners
- Cohance works with the top 20 global drug innovators, which account for over 85% of its small-molecule revenue.27
- Cohance is the exclusive supplier of a payload intermediate (a building block of the drug an ADC carries) for a major innovator's ADC pipeline, and makes patented active ingredients for large US and European agrochemical companies.27
- NJ Bio works with over 100 innovator and biotech accounts.28
Research and development
What the company expects
- On its earnings call of 5 Aug 2026, the company said it expects a return to year-on-year growth in the second half of the year to Mar 2027, and an EBITDA margin for that year closer to the previous year's margin percentage.2532
- In its presentation of 5 Aug 2026, the company said 2 Pharma CDMO customer molecules had entered commercial supply, with deliveries scheduled through Dec 2026, and 2 more were expected within 12 to 15 months.33
- On its earnings call of 5 Aug 2026, the company said it had defined a path to full ownership of Sapala Organics, whose chief executive, P.Y. Reddy, has agreed to lead the combined nucleic-acid business.34
- On its earnings call of 5 Aug 2026, the company said it believes Speciality Chemicals can support double-digit growth from the year to Mar 2028, subject to customer qualification and regulatory timelines.35
Litigation and regulatory matters
- On 4 Feb 2026 the company disclosed a US FDA warning letter (a formal notice of violations) for its Nacharam formulations plant, inspected 4 to 12 Aug 2025; US sales from the plant were under 2% of consolidated revenue in the year to Mar 2025.36
- In its presentation of 5 Aug 2026, the company said Nacharam's operations had resumed and US supplies had restarted; its documents give no outcome on the warning letter.37
- A US FDA inspection of the Pashamylaram, Hyderabad plant (27 Jul to 5 Aug 2026) ended with a Form 483 of 5 observations (inspectors' findings to be answered), none on data integrity; the company's documents give no outcome.38
- Inspections of the Shamshabad formulation plant (27 Aug to 4 Sep 2026) and the Jaggaiahpet API plant (14 to 19 Sep 2026) ended with Form 483s of 4 and 5 observations; the company's documents give no outcome.3940
Last updated
All 40 sources, each with its page
- 1. Annual report, 26 Aug 2026, page 20
- 2. Annual report, 26 Aug 2026, page 41
- 3. Annual report, 26 Aug 2026, page 140
- 4. Annual report, 26 Aug 2026, page 16
- 5. Annual report, 26 Aug 2026, page 146
- 6. Annual report, 26 Aug 2026, page 164
- 7. Investor presentation, 5 Aug 2026, page 15
- 8. Annual report, 26 Aug 2026, page 25
- 9. Annual report, 26 Aug 2026, page 17
- 10. Annual report, 26 Aug 2026, page 145
- 11. Annual report, 26 Aug 2026, page 23
- 12. Annual report, 26 Aug 2026, page 17
- 13. Investor presentation, 5 Aug 2026, page 8
- 14. Investor presentation, 5 Aug 2026, page 12
- 15. Investor presentation, 5 Aug 2026, page 8
- 16. Investor presentation, 5 Aug 2026, page 22
- 17. Earnings call, 5 Aug 2026, page 6
- 18. Earnings call, 5 Aug 2026, page 7
- 19. Annual report, 26 Aug 2026, page 137
- 20. Annual report, 26 Aug 2026, page 165
- 21. Annual report, 26 Aug 2026, page 37
- 22. Annual report, 26 Aug 2026, page 34
- 23. Annual report, 26 Aug 2026, page 41
- 24. Annual report, 26 Aug 2026, page 45
- 25. Earnings call, 5 Aug 2026, page 8
- 26. Annual report, 26 Aug 2026, page 42
- 27. Annual report, 26 Aug 2026, page 78
- 28. Annual report, 26 Aug 2026, page 61
- 29. Annual report, 26 Aug 2026, page 34
- 30. Annual report, 26 Aug 2026, page 63
- 31. Annual report, 26 Aug 2026, page 59
- 32. Earnings call, 5 Aug 2026, page 16
- 33. Investor presentation, 5 Aug 2026, page 25
- 34. Earnings call, 5 Aug 2026, page 3
- 35. Earnings call, 5 Aug 2026, page 7
- 36. Exchange filing, 4 Feb 2026, page 1
- 37. Investor presentation, 5 Aug 2026, page 29
- 38. Exchange filing, 5 Aug 2026, page 1
- 39. Exchange filing, 5 Sep 2026, page 1
- 40. Exchange filing, 21 Sep 2026, page 1
Results
Consolidated; ₹ crore.Cohance Lifesciences quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +41.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- −58.5%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹422 Crdown 31.80%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing. Net profit in the glossary
- −₹45 CrQuarter to Mar 2026: ₹8.31 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- −10.7%
Revenue by quarter
Peak revenue ₹619 Cr, quarter to Mar 2026; lowest ₹258 Cr, quarter to Sep 2024
Net profit by quarter, a loss in red
- Net profit
- Loss
A loss in the quarter to Jun 2026, −₹45 CrA loss in 1 of the 8 quarters shown
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 258 | 307 | 402 | 549 | 556 | 545 | 619 | 422 |
| Net profit | 82 | 83 | 39 | 46 | 66 | 29 | 8 | −45 |
| Net margin | 31.8% | 27.1% | 9.6% | 8.4% | 11.9% | 5.3% | 1.3% | −10.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹2,269 Crup 89.43%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹150 Crdown 43.30%
- Net margin
- 6.6%
Revenue by year
Peak revenue ₹2,269 Cr, year to Mar 2026; lowest ₹834 Cr, year to Mar 2020
Net profit by year, a loss in red
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 1,198 | 2,269 |
| Net profit | 317 | 362 | 454 | 411 | 300 | 265 | 150 |
| Net margin | 38.0% | 35.9% | 34.4% | 30.7% | 28.6% | 22.1% | 6.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.Cohance Lifesciences PE ratio and valuation
Price to earnings
At or below today's level on 87% of 1,240 trading days over the last 5 years.
LowestHighest
Its median45.40Industry median27.53
Price to book
At or below today's level on 11% of 1,114 trading days over the last 5 years.
LowestHighest
Its median8.26Industry median2.88
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 63% of 1,240 trading days over the last 5 years.
LowestHighest
Its median0.00%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −73.8% | −55.4% | −41.3% | 0.0% |
| 3 years | −13.9% | −33.8% | +30.0% | 0.0% |
| 5 years | −9.1% | −19.9% | +13.0% | 0.4% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2026.
Mutual fund holdings
106 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 47 of the 58 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 106 funds holding Cohance Lifesciences
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 3
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 3
- AddedAdded. Funds that held more shares than at the end of the month before.
- 23
- CutCut. Funds that held fewer shares than at the end of the month before.
- 35
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 42
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 9
| Fund | |||
|---|---|---|---|
 ICICI Prudential Healthcare FundICICI Prudential Mutual Fund | 62,66,692 | 4.06% | ₹278.2 Cr |
 SBI Multi Asset Allocation FundSBI Mutual Fund | 52,00,000 | 1.10% | ₹230.9 Cr |
 Invesco India Contra FundInvesco Mutual Fund | 43,93,667 | 1.01% | ₹195.1 Cr |
 HDFC Balanced Advantage FundHDFC Mutual Fund | 41,43,548 | 0.18% | ₹184.0 Cr |
 DSP Healthcare FundDSP Mutual Fund | 32,02,999 | 3.79% | ₹142.2 Cr |
 Bandhan Small Cap FundBandhan Mutual Fund | 31,27,757 | 0.39% | ₹138.9 Cr |
| SBI Balanced Advantage FundSBI Mutual Fund | 30,00,000 | 0.33% | ₹133.2 Cr |
| DSP Aggressive Hybrid FundDSP Mutual Fund | 23,47,265 | 0.92% | ₹104.2 Cr |
| SBI Healthcare Opportunities FundSBI Mutual Fund | 22,00,000 | 1.66% | ₹97.7 Cr |
| SBI MNC FundSBI Mutual Fund | 22,00,000 | 1.53% | ₹97.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 31 Oct 2025.Cohance Lifesciences insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 2 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Cohance Lifesciences competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Cohance Lifesciences in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Shilpa MedicareSHILPAMED | 18,690 | 62.86 | 7.21 | +27.9% | +167.6% | 12.0% | 10.9% | 0.06% |
 Onesource Specialty PharmaONESOURCE | 17,924 | – | 3.03 | +10.7% | −103.9% | 0.0% | 1.5% | 0.00% |
 Caplin Point LaboratoriesCAPLIPOINT | 17,677 | 26.57 | 4.93 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 Alivus Life SciencesALIVUS | 17,376 | 25.94 | 4.79 | +8.2% | +26.3% | 20.2% | 23.1% | 0.35% |
 PfizerPFIZER | 16,871 | 22.95 | 4.01 | +10.7% | −9.1% | 17.5% | 21.0% | 2.03% |
 Eris LifesciencesERIS | 16,044 | 22.67 | 3.87 | +11.1% | +70.2% | 19.6% | 13.4% | 0.62% |
 AstraZeneca Pharma IndiaASTRAZEN | 15,911 | 93.81 | 18.23 | +31.1% | −7.5% | 20.6% | 24.4% | 0.57% |
 Alembic PharmaceuticalsAPLLTD | 15,683 | 22.69 | 2.76 | +14.1% | +14.6% | 12.7% | 11.8% | 1.50% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Cohance Lifesciences dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹6.00 a share, year to Mar 2023.
| Ex-date | Type | Per share |
|---|---|---|
| 9 Sep 2022 | Interim | ₹1.00 |
| 9 Sep 2022 | Special | ₹5.00 |
| 13 May 2022 | Interim | ₹1.00 |
| 13 May 2022 | Special | ₹1.00 |
| 15 Feb 2022 | Interim | ₹1.00 |
| 15 Feb 2022 | Special | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Cohance Lifesciences announcements
Oct 2026
27 Oct · Analysts
26 Oct · Board meeting
12 Oct
9 Oct · General Updates
6 Oct · General Updates
Cohance Lifesciences share price by year
Each calendar year to 2025.Cohance Lifesciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 528.60 | −53.6% | 1,230.00 | 525.70 |
| 2024 | 1,138.75 | +57.5% | 1,334.20 | 610.45 |
| 2023 | 722.80 | +46.0% | 722.80 | 464.90 |
| 2022 | 494.90 | +0.3% | 621.15 | 395.05 |
| 2021 | 493.25 | +9.1% | 579.05 | 439.40 |
| 2020 | 452.30 | – | 476.60 | 95.43 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2020 is from its first session, 9 Mar 2020.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 476.20 | 493.05 | 473.20 | 481.35 | 484.05 | 14,95,780 | 37.5% |
| 28 Oct 2026 | 484.00 | 487.40 | 471.70 | 476.05 | 479.20 | 6,27,122 | 43.3% |
| 27 Oct 2026 | 463.00 | 483.70 | 460.55 | 479.25 | 474.69 | 12,27,886 | 35.6% |
| 26 Oct 2026 | 452.00 | 465.75 | 450.00 | 463.55 | 460.86 | 4,17,497 | 37.7% |
| 23 Oct 2026 | 453.00 | 454.00 | 437.40 | 449.85 | 446.93 | 5,73,702 | 51.1% |
| 22 Oct 2026 | 456.70 | 461.40 | 451.05 | 453.85 | 455.62 | 4,11,587 | 68.7% |
| 21 Oct 2026 | 464.90 | 470.75 | 453.00 | 461.80 | 463.62 | 7,30,876 | 27.4% |
| 19 Oct 2026 | 468.00 | 468.00 | 456.00 | 457.70 | 460.69 | 3,54,458 | 53.2% |
| 16 Oct 2026 | 460.45 | 467.35 | 458.10 | 464.05 | 464.25 | 7,63,452 | 73.1% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 25 Sep 2020 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- COHANCE
- BSE code
- 543064
- ISIN
- INE03QK01018
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- SUVENPHAR
- Website
- www.cohance.com
- CIN
- L24299MH2018PLC422236
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2018
- Registered office
- 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai 400093, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Smallcap 250, BSE 250 SmallCap Index, Nifty Smallcap 100, BSE SmallCap